Dare Bioscience Inc is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions, particularly in women's health care
The company is dedicated to addressing unmet medical needs by creating products aimed at enhancing reproductive health, contraception, and various gynecological conditions. With a portfolio of proprietary and partnered therapies, Dare Bioscience combines scientific expertise and cutting-edge technologies to deliver effective treatment options that improve the quality of life for women.
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo.
Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of awareness. ARPA-H Sprint for Women's Health aims to promote innovative solutions.
Companies Reporting Before The Bell • Universal Stainless (NASDAQUSAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
Daré Bioscience Inc (NASDAQDARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1 an investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginall
Daré Bioscience Inc (NASDAQDARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of VVA
